PROSTA-5,13-DIEN-1-OIC ACID, 11,15-DIHYDROXY-16,16-DIMETHYL-9-OXO-, (5Z,11.ALPHA.,13E,15R)
Acute Lymphoblastic Leukemia (ALL)
Fate TherapeuticsSmall moleculePhase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 32/ 100
- Competitive Position
- 95/ 100
Competitive context
253 Active assets in the Acute Lymphoblastic Leukemia (ALL) cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Gm-Csf Xinhua Hospital, Shanghai Jiao Tong University School of Medicine | Phase 4 | BBB |
Allogeneic Cd34+-Enriched And Cd45Ra-Depleted Pbscs Fred Hutchinson Cancer Center | Phase 2/3 | BBB |
THIOGUANINE ANHYDROUS St. Jude Children's Research Hospital | Phase 4 | BBB |
Equine Atg Instituto Nacional de Cancer, Brazil | Phase 3 | BBB |
MERCAPTOPURINE ANHYDROUS Dana-Farber Cancer Institute | Phase 4 | BB |
View all 50 →
Same molecule, other indications
PROSTA-5,13-DIEN-1-OIC ACID, 11,15-DIHYDROXY-16,16-DIMETHYL-9-OXO-, (5Z,11.ALPHA.,13E,15R) is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →